I
n a significant milestone, Grove Biopharma has taken up residence in a sprawling 17,000-square-foot space within Trammell Crow's Fulton Labs, marking a major expansion for the biotech firm. This move comes hot on the heels of securing $30 million in funding, underscoring the company's rapid growth trajectory.

    Trammell Crow's life sciences portfolio has been gaining momentum, with notable projects sprouting up in Evanston and Hyde Park. The developer's commitment to this sector is evident in its extensive holdings, boasting over 1.2 million square feet of office space across various properties.

    Grove Biopharma's journey from humble beginnings as a university spinoff to its current status as a prominent biotech player has been nothing short of remarkable. The company's transition from shared incubator space within the same building to its new, larger digs is a testament to the thriving life sciences ecosystem in Chicago.

    Trammell Crow's Midwest unit has hailed Grove Biopharma as a prime example of the developer's thesis for Fulton Labs: nurturing companies that spin out of top-tier universities and grow into successful biotech players. As Morgan Baer Blaskao noted, "Grove Biopharma is the perfect embodiment of our vision for Fulton Labs – from incubation to growth and expansion."

    Despite concerns about oversupply in the life sciences sector nationwide, Trammell Crow remains committed to its Chicago-based projects. The developer's confidence in this market is reflected in its extensive holdings, which include Evanston Labs and Hyde Park labs.

    However, not all life sciences developments have been as successful. Sterling Bay's Lincoln Yards megaproject, featuring a life sciences building, has yet to secure any tenants, while the rest of the project remains stalled. Meanwhile, other developers have pivoted or abandoned their life sciences plans in favor of more lucrative projects.